1-Hydroxybenzotriazole → 2-(1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)-N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]acetamide

HRID 877026

Reaktionsgleichung

Reaktionsgleichung von HRID 877026
[CH3:1][N:2]1[C:7]2=[CH:8][S:9][C:10](C)=[C:6]2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14].[F:15][C:16]([F:24])([F:23])[C:17]1[N:18]=[C:19]([NH2:22])[S:20][CH:21]=1.CCN=C=NC[CH2:31][CH2:32]N(C)C.Cl.C1C=CC2N([OH:46])N=NC=2C=1>CN(C1C=CN=CC=1)C.ClCCCl>[CH3:1][N:2]1[C:10]2[S:9][CH:8]=[C:7]([CH2:31][C:32]([NH:22][C:19]3[S:20][CH:21]=[C:17]([C:16]([F:24])([F:23])[F:15])[N:18]=3)=[O:46])[C:6]=2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14]

Komponenten

7

Versuchsvorschrift

The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.393 mmol) with 4-(trifluoromethyl)-1,3-thiazol-2-amine (66 mg, 0.393 mmol) in the presence of EDCI hydrochloride (90 mg, 0.471 mmol), HOBt (16 mg, 0.118 mmol) and DMAP (5 mg, 0.039 mmol) in 1,2 dichloroethane (4 ml) to give 27 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 3.18 (s, 3H), 3.46 (s, 3H), 4.05 (s, 2H), 7.07 (s, 1H), 7.91 (s, 1H), 12.70 (br s, 1H); APCI-MS (m/z) 404.97 (M+H)+.

Quellen und Nachweise

ORD-Eintrag
ord-f2f002be385c43dab5743f6b12e5841b
Quelldatensatz
uspto-grants-2015_03
Patentnummer
US08987278B2

Verknüpfte Notizen

Wird geladen…